Drug Trial Radar · NCT07285122
Inhaled RB042 in Healthy Adult Volunteers, Healthy Adult Smokers and Patients With Chronic Obstructive Pulmonary Disease
Last checked: Nov 20, 2026Latest source record: Aug 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
105
Planned (sponsor's estimate)
Start
Feb 16, 2026
Primary completion
Oct 2027
Study completion Oct 2027
Sponsor
- Lead sponsor
- Atisama TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Dec 16, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a 4-part, randomised, double-blind, placebo-controlled, first in human study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of inhaled RB042.
Conditions
- Healthy
- Healthy Smoker
- COPD (Chronic Obstructive Pulmonary Disease)
- COPD
Interventions
RB042Drug
A single or multiple doses of RB042 will be administered via a nebuliser.
Placebo inhalation solutionDrug
A single or multiple doses of placebo will be administered via a nebuliser.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number and frequency of treatment-emergent adverse events (TEAEs)Time frame: From Day 1 until the end of the study (Day 85 for Part A; Day 106 for Parts B and D)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Linear Clinical Research
Nedlands, Western Australia, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.